GlassScriptPhysician profile
Tina Vo
NPI 1083365951
$3,100.11
in general payments reported to CMS, 2019-2025
25 companies · $549 in 2025
The $549 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $439 · 2023: $1,168 · 2024: $944 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,660.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $338.66 | 2022-2024 | Farxiga |
| Glaxosmithkline, LLC. | $335.50 | 2023-2025 | |
| Abbvie INC. | $250.34 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $189.15 | 2022-2023 | Elaprase |
| Novo Nordisk INC | $154.89 | 2023 | Wegovy |
| Cequr Corporation | $150.00 | 2024 | Cequr Simplicity |
| Heartflow, INC. | $148.11 | 2025 | |
| Dexcom, INC. | $136.45 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Genzyme Corporation | $122.68 | 2023 | |
| Sage Therapeutics, LLC | $119.97 | 2023 | |
| Amgen INC. | $99.36 | 2024 | Evenity |
| Janssen Pharmaceuticals, INC | $95.12 | 2022 | |
| Xeris Pharmaceuticals, INC. | $95.01 | 2023 | Recorlev |
| Gilead Sciences, INC. | $94.45 | 2023 | Epclusa |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $88.31 | 2022 | |
| Astellas Pharma US INC | $85.50 | 2024 | Veozah |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $81.67 | 2023 | Lifevest |
| Viiv Healthcare Company | $76.11 | 2024 | Apretude |
| Calliditas Therapeutics US INC. | $71.41 | 2025 | Tarpeyo |
| Madrigal Pharmaceuticals | $67.86 | 2025 | Rezdiffra |
| Kyowa Kirin, INC. | $61.48 | 2023 | |
| Biomarin Pharmaceutical INC. | $56.05 | 2023 | Voxzogo 1.2mg |
| Mylan Specialty L.P. | $41.77 | 2023 | Yupelri |
| Dysis Medical, INC. | $15.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tina Vo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.